Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.
Treatment with chimeric antigen receptor (CAR) T-cell therapies in B-cell cancers, like certain types of lymphoma and leukemia, is associated with ... Read more
Results from a recent large-scale study indicate that stem cell transplants should be considered for the treatment of patients with relapsed ... Read more
Stem cell transplants can lead to excellent outcomes in certain B-cell lymphoma patients who failed to respond to chemoimmunotherapy, a study shows. ... Read more
Treatment with KD025 is safe and effectively reduces the manifestations of graft-versus-host disease in patients receiving steroids for the condition, or ... Read more
Capture hybridization-based sequencing, a gene sequencing technique, is superior for the detection of lymphoid cancer-associated mutations in a panel of 32 ... Read more
The tumor suppressor PD-1, which serves as shut-off switch to prevent damaged T-cells from continuing to develop and proliferate, is frequently ... Read more
Juno Therapeutics‘ immunotherapy JCAR017 eliminated a brain tumor in a patient whose lymphoma had spread to her brain, researchers at Massachusetts ... Read more
Pfizer Inc. announced that the FDA has approved Besponsa (inotuzumab ozogamicin) for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic ... Read more
Therapies called STING agonists help overcome the resistance that lymphoma patients develop to monoclonal antibodies such as Rituxan (rituximab), a study reports. ... Read more